epirubicin has been researched along with Leukemia in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (27.27) | 18.7374 |
| 1990's | 7 (31.82) | 18.2507 |
| 2000's | 6 (27.27) | 29.6817 |
| 2010's | 2 (9.09) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Hristova-Avakumova, NG; Momekov, GT; Zhelyazkova, MY | 1 |
| Abdeen, S; Alexander, P; Bhagat, M; Chavali, M; Praseetha, PK; Rose, PA | 1 |
| Austin, CA; Cowell, IG | 1 |
| Bramwell, V; Crump, M; Levine, M; Pritchard, K; Shepherd, L; Tu, D | 1 |
| Seiter, K | 1 |
| Hill, RJ; Mahjoubi, F; Peters, GB | 1 |
| Cognetti, F; Ferretti, G; Papaldo, P | 1 |
| Hu, XF; Li, J; Vandervalk, S; Xing, PX; Yang, E | 1 |
| Eridani, S; Pearson, TC; Singh, AK; Slater, NG | 1 |
| Adachi, K; Collins, PW; Gutteridge, CN; Jiang, XR; Kelsey, SM; Macey, MG; Miki, T; Newland, AC; Yamabe, S | 1 |
| Davey, MW; Davey, RA; Kidman, AD; Marks, DC | 1 |
| Riggi, M; Riva, A | 1 |
| Marty, M | 1 |
| Arbona, C; Benet, I; Comes, AM; García Clavel, B; García-Conde, J; Lluch, A; Martínez-Climent, JA; Marugán, I; Prósper, F; Solano, C; Vizcarra, E | 1 |
| Adachi, K; Jenkins, GC; Jiang, XR; Macey, MG; Miki, T; Newland, AC; Yamabe, S | 1 |
| Capalbo, S; Dione, R; Liso, V; Pavone, V; Specchia, G | 1 |
| Ancheva, M; Mircheva, J; Staneva-Stoytcheva, D | 1 |
| Paul, C; Sundman-Engberg, B; Tidefelt, U | 1 |
| Raymond, V; Young, CW | 1 |
| Cersosimo, RJ; Hong, WK | 1 |
| Kobayashi, T; Kozuru, M; Masaoka, T; Oguro, M; Sampi, K; Shibata, H; Shirai, T; Shirakawa, S; Sugiyama, H; Umeda, M | 1 |
| Furuta, I; Katayama, N; Kobayashi, T; Matsuoka, N; Ohno, T; Ohta, C; Shima, N; Shimizu, N; Tanaka, I; Uchida, T | 1 |
3 review(s) available for epirubicin and Leukemia
| Article | Year |
|---|---|
Toxicity of the topoisomerase II inhibitors.
Topics: Antineoplastic Agents; Cardiovascular Diseases; Daunorubicin; Doxorubicin; Enzyme Inhibitors; Epirubicin; Etoposide; Humans; Idarubicin; Leukemia; Middle Aged; Mitoxantrone; Mucositis; Podophyllotoxin; Teniposide; Topoisomerase II Inhibitors; Vascular Diseases | 2005 |
Clinical assessment of the structure-activity relationship of anthracyclines and related synthetic derivatives.
Topics: Aclarubicin; Anthraquinones; Antibiotics, Antineoplastic; Breast Neoplasms; Carubicin; Cell Survival; Daunorubicin; Doxorubicin; Drug Evaluation; Epirubicin; Heart; Humans; Idarubicin; Leukemia; Menogaril; Mitoxantrone; Naphthacenes; Nogalamycin; Sarcoma; Structure-Activity Relationship | 1986 |
Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue.
Topics: Bone Marrow; Breast Neoplasms; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colonic Neoplasms; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Epirubicin; Female; Head and Neck Neoplasms; Heart; Humans; Kidney Neoplasms; Kinetics; Leukemia; Liver Neoplasms; Lung Neoplasms; Lymphoma; Male; Melanoma; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Rectal Neoplasms; Soft Tissue Neoplasms; Stomach Neoplasms; Urinary Bladder Neoplasms | 1986 |
1 trial(s) available for epirubicin and Leukemia
| Article | Year |
|---|---|
A pilot study of epidoxorubicin (NSC 256942) in combination treatment of acute leukaemia and non-Hodgkin's lymphoma.
Topics: Acute Disease; Adult; Aged; Antibiotics, Antineoplastic; Clinical Trials as Topic; Doxorubicin; Epirubicin; Female; Humans; Leukemia; Lymphoma; Male; Middle Aged | 1984 |
18 other study(ies) available for epirubicin and Leukemia
| Article | Year |
|---|---|
Antitumor activity of the combination of artemisinin and epirubicin in human leukemia cells.
Topics: Anthracyclines; Artemisinins; Deoxyribose; Doxorubicin; Drug Synergism; Epirubicin; Humans; Iron; Lecithins; Leukemia | 2021 |
Drug embedded PVP coated magnetic nanoparticles for targeted killing of breast cancer cells.
Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Chemistry, Pharmaceutical; Coated Materials, Biocompatible; Drug Delivery Systems; Epirubicin; Female; Folic Acid; Humans; Leukemia; Lung Neoplasms; Magnetite Nanoparticles; Male; Pharmaceutic Aids; Povidone; Prostatic Neoplasms; Spectroscopy, Fourier Transform Infrared | 2013 |
Do transcription factories and TOP2B provide a recipe for chromosome translocations in therapy-related leukemia?
Topics: Anthracyclines; DNA Breaks, Double-Stranded; DNA Topoisomerases, Type II; DNA-Binding Proteins; Epirubicin; Etoposide; Humans; Leukemia; Mitoxantrone; Models, Genetic; Neoplasms, Second Primary; Poly-ADP-Ribose Binding Proteins; Translocation, Genetic | 2012 |
Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Cytarabine; Epirubicin; Female; Fluorouracil; Humans; Leukemia; Methotrexate; Middle Aged; Neoplasms, Multiple Primary; Risk | 2003 |
Chromosome microdissection identifies genomic amplifications associated with drug resistance in a leukemia cell line: an approach to understanding drug resistance in cancer.
Topics: Antibiotics, Antineoplastic; Cell Line, Tumor; Chromosomes, Human; DNA, Neoplasm; Drug Resistance, Neoplasm; Epirubicin; Gene Amplification; Genes, MDR; Humans; In Situ Hybridization, Fluorescence; Leukemia; Microdissection; Multidrug Resistance-Associated Proteins; T-Lymphocytes | 2006 |
Lineage-specific hematopoietic growth factors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Granulocyte Colony-Stimulating Factor; Humans; Leukemia; Neoplasms, Second Primary | 2006 |
Anti-Cripto Mab inhibit tumour growth and overcome MDR in a human leukaemia MDR cell line by inhibition of Akt and activation of JNK/SAPK and bad death pathways.
Topics: Animals; Antibodies, Monoclonal; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; bcl-Associated Death Protein; bcl-X Protein; Caspase 9; Cell Growth Processes; Cell Line, Tumor; Cytarabine; Daunorubicin; Drug Synergism; Enzyme Activation; Epirubicin; Female; Humans; Intercellular Signaling Peptides and Proteins; Leukemia; MAP Kinase Kinase 4; Mice; Mice, SCID; Mitogen-Activated Protein Kinases; Oncogene Protein v-akt; Proto-Oncogene Proteins c-bcl-2 | 2007 |
Structure-dependent antitumor activities of novel anthracyclines YM1, YM3, YM4 and YM6: drug transport properties and effects on biomacromolecule synthesis in drug sensitive and resistant leukemia cells.
Topics: Biological Transport; DNA; Doxorubicin; Drug Resistance; Epirubicin; Humans; Leukemia; Protein Biosynthesis; RNA; Structure-Activity Relationship; Tumor Cells, Cultured | 1993 |
Expression of multidrug resistance in response to differentiation in the K562 human leukaemia cell line.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Butyrates; Butyric Acid; Cell Differentiation; Cell Survival; Colchicine; Drug Resistance, Multiple; Epirubicin; Humans; Leukemia; Phenotype; Rhodamine 123; Rhodamines; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured; Verapamil | 1995 |
Therapy-related leukemia: what is the role of 4-epi-doxorubicin?
Topics: Epirubicin; Humans; Leukemia; Neoplasms, Second Primary | 1993 |
Epirubicin and the risk of leukemia: not substantiated? International Collaborative Cancer Group Steering Committee.
Topics: Epirubicin; Humans; Leukemia; Neoplasms, Second Primary | 1993 |
Chromosomal abnormalities in women with breast cancer after autologous stem cell transplantation are infrequent and may not predict development of therapy-related leukemia or myelodysplastic syndrome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neoplasms; Chemotherapy, Adjuvant; Chromosome Aberrations; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Fluorouracil; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Middle Aged; Myelodysplastic Syndromes; Neoplasm Staging; Neoplasms, Second Primary; Postmenopause; Predictive Value of Tests; Premenopause; Transplantation, Autologous | 2000 |
Evaluation of the in vitro antiproliferative properties of four novel anthracyclines YM1, 3, 4 and 6 in human leukemia cell lines.
Topics: Antineoplastic Agents; Cell Division; Doxorubicin; Drug Resistance; Drug Screening Assays, Antitumor; Epirubicin; Humans; Leukemia; Tumor Cells, Cultured | 1992 |
Continuous infusion chemotherapy with epirubicin and vincristine in relapsed and refractory acute leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Epirubicin; Female; Humans; Infusions, Intravenous; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vincristine | 1990 |
Ryodipine-induced enhancement of farmarubicin cytotoxicity against human leukemia cells in vitro.
Topics: Calcium Channel Blockers; Cell Survival; Drug Synergism; Epirubicin; Humans; Leukemia; Nifedipine; Tumor Cells, Cultured | 1990 |
Comparison of the intracellular pharmacokinetics of doxorubicin and 4'-epi-doxorubicin in patients with acute leukemia.
Topics: Acute Disease; Chromatography, High Pressure Liquid; Doxorubicin; Drug Interactions; Epirubicin; Humans; Leukemia; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Tumor Cells, Cultured | 1989 |
[A phase II study of epirubicin in acute leukemia: a cooperative group study].
Topics: Acute Disease; Adult; Aged; Anorexia; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Epirubicin; Female; Humans; Leukemia; Male; Middle Aged; Nausea; Stomatitis | 1986 |
[Single-agent trial with epirubicin in hematological malignancies].
Topics: Acute Disease; Adult; Aged; Doxorubicin; Drug Evaluation; Epirubicin; Female; Humans; Leukemia; Lymphoma; Male; Middle Aged | 1987 |